Eagle Global Advisors’s AstraZeneca AZN Stock Holding History

Eagle Global Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.13M	Buy	37,609 +128	+0.3%	+$24.1K	0.24%	83
2026 Q1	$7.39M	Buy	37,481 +10,880	+41%	+$2.1M	0.27%	72
2025 Q4	$4.89M	Sell	26,601 -167	-0.6%	-$29.3K	0.18%	99
2025 Q3	$4.11M	Hold	26,768	–	–	0.16%	105
2025 Q2	$3.74M	Buy	26,768 +80	+0.3%	+$11.2K	0.15%	103
2025 Q1	$3.92M	Sell	26,688 -1,265	-5%	-$183K	0.16%	99
2024 Q4	$3.66M	Sell	27,953 -1,675	-6%	-$235K	0.15%	100
2024 Q3	$4.62M	Sell	29,628 -290	-1%	-$46.8K	0.23%	79
2024 Q2	$4.67M	Buy	29,918 +1,712	+6%	+$258K	0.25%	77
2024 Q1	$3.82M	Buy	28,206 +8,013	+40%	+$1.06M	0.22%	81
2023 Q4	$2.72M	Sell	20,193 -557	-3%	-$72.4K	0.16%	99
2023 Q3	$2.81M	Buy	20,750 +7,712	+59%	+$1.05M	0.18%	97
2023 Q2	$1.87M	Buy	13,038 +740	+6%	+$109K	0.12%	118
2023 Q1	$1.71M	Buy	+12,298	New	+$1.65M	0.12%	120

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Eagle Global Advisors's AZN Position: Q2 2026 in Review

Eagle Global Advisors increased its AstraZeneca (AZN) stake by 0.34% in Q2 2026, buying an estimated $24.1K and bringing the position to 37,609 shares worth $7.13M. The position accounts for 0.24% of the portfolio, ranked #83.

Eagle Global Advisors first reported a position in AZN in Q1 2023 and has held it in 14 quarters since. The position peaked at $7.39M in Q1 2026. 1,503 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Eagle Global Advisors held 37,609 shares of AstraZeneca worth $7.13M as of Q2 2026.
Eagle Global Advisors bought 128 AstraZeneca shares in Q2 2026, an estimated $24.1K.
AstraZeneca made up 0.24% of Eagle Global Advisors's portfolio in Q2 2026, its #83 holding.
Eagle Global Advisors first reported a position in AstraZeneca in Q1 2023 and has held it in 14 quarters since.
Eagle Global Advisors's AstraZeneca position peaked at $7.39M in Q1 2026.
1,503 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Eagle Global Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.